Search the Newsreel

Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake

Farallon Capital Management, L.L.C., along with several related investment entities and individuals, has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 6,000 shares of Tyra Biosciences (TYRA) common stock, which constitutes a 0% stake as of June 30, 2026. …

Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

Styrenix Performance Materials Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Tyranna Resources (ASX:TYX): Why Is Its Mining Reset in Focus?

Tyranna Resources (ASX:TYX): What Is Driving Its Mining Story?

Why Is Tyranna Resources (ASX:TYX) Back in Market Focus?

Insiders In Tyranna Resources Left Out From 33% Price Rise After Disposing Stock

Avoiding Lag: Real-Time Signals in (TYRA) Movement

The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.

Tolins Tyres Q1 Results FY27: Revenue Rs 79 crore, Net Profit Rs 6 Crore

Tolins Tyres consolidated net profit declines 33.44% in the June 2026 quarter

Styrenix posts 166% profit surge in Q1FY27 despite volume dip

Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright

Earnings Report: JK Tyre & Industries Limited Missed Revenue Estimates By 13%

aTyr, Biogen, City name legal chiefs

Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their …

Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside

Analysts have slightly cut the average 12-month price target for Tyra Biosciences, Inc. (TYRA) stock from $51.09 to $50.82, with individual forecasts ranging from $39 to $59. This updated target suggests a potential upside of approximately 94% based on the recent closing price. The …

Apollo Tyres CFO Gaurav Kumar resigns; India revenue hits record high in Q1FY27

Why is aTyr Pharma stock gaining today?

aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors …

Tyranna Resources Issues Over 26 Million Unquoted Options

Tyranna Resources Seeks ASX Quotation for 17.4 Million New Shares

ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3

(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development …

Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025

Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between …

aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug

aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its …

Results: Apollo Tyres Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

ATyr Pharma Announces Second Quarter 2026 Res

This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.

Tyranna Shareholders Back Angolan Acquisition and Strategic Asset Shift

aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary

aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its …

aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD

aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial …

ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus

aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing …

Atyr Pharma: Q2 Earnings Snapshot

HC Wainwright Brokers Lower Earnings Estimates for TYRA

Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Top stocks in news: LIC, Britannia, TVS Motor, Premier, Dabur, Apollo Tyres, Alkem Labs

aTyr Pharma (ATYR) Earnings Date and Reports 2026